News from the FDA/CDC
FDA/CDC
Fluoroquinolones can cause fatal hypoglycemia, FDA warns
News from the FDA/CDC
FDA approves Aristada Initio for schizophrenia
Aristada Initio, a long-acting injectable atypical antipsychotic, is the first on the market to have a 2-month dosing option.
FDA/CDC
Cost led to missed care for 4.5% of Americans in 2017
Steady decline in national rate appears to have halted.
News from the FDA/CDC
Youth tobacco use shows ‘promising declines’
E-cigarettes are now the most popular form of tobacco among middle school students and third among high school students.
FDA/CDC
Bipolar and seizure medication linked with serious immune system reaction
Lamotrigine will carry a warning about hemophagocytic lymphohistiocytosis.
News from the FDA/CDC
Suicide on the minds of many Utah teens
Bullying and substance use may be factors in the state’s increasing youth suicide rate.
FDA/CDC
CDC: Marijuana use may spur industries to rethink current policies
A new report from the CDC clears some of the smoke around marijuana use.
Reader Poll
Pregnant women in clinical trials: FDA questions how to include them
Lack of research can be harmful to mother and fetus, FDA draft guidance says, and it can be “ethically justifiable” to include them in studies.
FDA/CDC
FDA recalls kratom products for salmonella contamination
Agency issues its first-ever mandatory recall of the controversial herbal product.
News from the FDA/CDC
Synthetic opioids drive increase in overdose deaths
Illegally manufactured fentanyl is now being combined with other drugs.
Latest News
FDA advisors recommend lofexidine for opioid withdrawal
SILVER SPRING, MD. – A nonopioid agent for symptomatic treatment of opioid withdrawal could be another option to address the opioid epidemic.